single20MG
Retatrutide
20MG Protocol
Retatrutide 20MG
Injection Freq.
Inject once weekly
Cycle Sched.
Minimum 24 weeks; trials extended to 48 weeks
Reconstitution
2.0 mL BAC water
Substantial weight loss reported in trials (up to ~24% at higher weekly doses)
HbA1c reductions (~2.0% reported in T2D trials at higher doses)
Improvements in lipids, blood pressure, and other cardiometabolic markers
Once-weekly dosing convenience
1
Reconstitution Requirements
- 2.0 mL BAC water
Escalation steps: 4
Defined through week 12
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 2 mg (2000 mcg) | 20 |
| 2 | Weeks 5–8 | 4 mg (4000 mcg) | 40 |
| 3 | Weeks 9–12 | 6 mg (6000 mcg) | 60 |
| 4 | Weeks 1+ | 8 mg (8000 mcg) | 80 |
Inject once weekly
Minimum 24 weeks; trials extended to 48 weeks
Retatrutide (Retatrutide) is described as a first-in-class triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to target weight and glucose physiology from three angles. The protocol explains the distinct role of each receptor: GLP-1 reduces appetite and slows gastric emptying; GIP enhances insulin secretion and may contribute to fat-metabolism effects; and glucagon receptor activation raises energy expenditure and promotes fat oxidation. This combination is presented as producing synergistic weight-loss and glycemic effects that exceed single- or dual-agonist incretin therapies. The page also notes engineering for duration—an approximately 6-day half-life supports once-weekly dosing. Clinical trial outcomes summarized include very large average body-weight reductions at higher weekly doses and meaningful HbA1c lowering in type 2 diabetes populations, alongside improvements in cardiometabolic markers. Overall, the mechanism is appetite reduction plus increased expenditure/fat oxidation, with GI side effects most common during dose escalation.
Nausea
Diarrhea
Vomiting
Constipation
Injection-site reactions (redness/swelling/discomfort)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)